Q-VD-OPh hydrate
To Order Contact us: bjorn@lembcke.dk
Q-VD-OPh hydrate |
|||
| GK2336-1MG | Glentham Life Sciences | 1 mg | EUR 316.8 |
Q-VD-OPh hydrate |
|||
| GK2336-5MG | Glentham Life Sciences | 5 mg | EUR 1033.2 |
Q-VD-OPh |
|||
| HY-12305 | MedChemExpress | 10mM/1mL | EUR 228 |
Q-VD-OPh |
|||
| 1170-1 | Biovision | each | EUR 280.8 |
Q-VD-OPh |
|||
| 1170-3 | Biovision | each | EUR 529.2 |
Q-VD-OPh |
|||
| 1170-5 | Biovision | each | EUR 874.8 |
Q-VD-OPh |
|||
| 1170-50 | Biovision | each | Ask for price |
Q-VD(OMe)-OPh |
|||
| A8165-1 | ApexBio | 1 mg | EUR 212.4 |
|
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor, provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors. |
|||
Q-VD(OMe)-OPh |
|||
| A8165-10 | ApexBio | 10 mg | EUR 756 |
|
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor, provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors. |
|||
Q-VD(OMe)-OPh |
|||
| A8165-25 | ApexBio | 25 mg | EUR 1173.6 |
|
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor, provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors. |
|||
Q-VD(OMe)-OPh |
|||
| A8165-5 | ApexBio | 5 mg | EUR 477.6 |
|
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor, provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors. |
|||
Q-VD(OMe)-OPh |
|||
| A8165-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 853.2 |
|
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor, provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors. |
|||
Q-VD(OMe)-OPh |
|||
| A8165-S | ApexBio | Evaluation Sample | EUR 97.2 |
|
Description: Q-VD-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad spectrum caspase inhibitor, provides a cost effective, non toxic, and highly specific means of apoptotic inhibition and provides new insight into the design of new inhibitors. |
|||
(R)-Q-VD-OPh |
|||
| HY-12305A | MedChemExpress | 10mg | EUR 308.4 |
EZSolution? Q-VD-OPh |
|||
| 1173-1 | Biovision | each | EUR 248.4 |
Q-VD(OMe)-OPh |
|||
| 27640-1 | BPS Bioscience | 5 mg | EUR 380 |
|
Description: Q-VD-(OMe)-Ph is a second-generation capase inhibitor that is highly potent, brain and cell permeable, irreversible and nontoxic. Q-VD-(OMe)-Ph can inhibit caspase-3 ( IC50=25 nm), caspase-1 (IC50=50 nM), caspase-8 (IC50=100 nM) and caspase-9 (IC50=430 nM). |
|||
Q-VD(OMe)-OPh |
|||
| 27640-2 | BPS Bioscience | 10 mg | EUR 565 |
|
Description: Q-VD-(OMe)-Ph is a second-generation capase inhibitor that is highly potent, brain and cell permeable, irreversible and nontoxic. Q-VD-(OMe)-Ph can inhibit caspase-3 ( IC50=25 nm), caspase-1 (IC50=50 nM), caspase-8 (IC50=100 nM) and caspase-9 (IC50=430 nM). |
|||
EZSolution? Q-VD-OPh, Negative Control |
|||
| 1174-1 | Biovision | each | EUR 248.4 |
Pan-caspase inhibitor, Q-VD(OMe)-OPh |
|||
| 2787-1 | Biovision | each | EUR 314.4 |
Pan-caspase inhibitor, Q-VD(OMe)-OPh |
|||
| 2787-5 | Biovision | each | EUR 966 |
Q-VE-Oph |
|||
| GL5302-1MG | Glentham Life Sciences | 1 mg | EUR 302.4 |
EZSolution? Q-DEVD-OPh |
|||
| 1178-1 | Biovision | each | EUR 326.4 |
Caspase-3 Inhibitor Q-DEVD-OPh |
|||
| 1175-1 | Biovision | each | EUR 326.4 |
Caspase-3 Inhibitor Q-DEVD-OPh |
|||
| 1175-3 | Biovision | each | EUR 639.6 |
Caspase-3 Inhibitor Q-DEVD-OPh |
|||
| 1175-5 | Biovision | each | EUR 966 |
Caspase-8 Inhibitor, Q-IETD-OPh |
|||
| 1176-1 | Biovision | each | EUR 366 |
Caspase-8 Inhibitor, Q-IETD-OPh |
|||
| 1176-3 | Biovision | each | EUR 823.2 |
Caspase-8 Inhibitor, Q-IETD-OPh |
|||
| 1176-5 | Biovision | each | EUR 1188 |
Caspase-9 Inhibitor, Q-LEHD-OPh |
|||
| 1177-1 | Biovision | each | EUR 352.8 |
Caspase-9 Inhibitor, Q-LEHD-OPh |
|||
| 1177-3 | Biovision | each | EUR 810 |
Caspase-9 Inhibitor, Q-LEHD-OPh |
|||
| 1177-5 | Biovision | each | EUR 1161.6 |
VD/ Rat VD ELISA Kit |
|||
| ELA-E0917r | Lifescience Market | 96 Tests | EUR 1063.2 |
QVD-OPh Negative Control |
|||
| 1171-1 | Biovision | each | EUR 248.4 |
QVD-OPh Negative Control |
|||
| 1171-3 | Biovision | each | EUR 483.6 |
QVD-OPh Negative Control |
|||
| 1171-5 | Biovision | each | EUR 705.6 |
VD-PEG-NH2,2K |
|||
| 33-HE090005-2K | Biochempeg |
|
|
|
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
|||
Creatine hydrate |
|||
| CB0326 | Bio Basic | 100g | EUR 73.57 |
Doripenem hydrate |
|||
| D004-25MG | TOKU-E | 25 mg | EUR 170.4 |
Doxycycline hydrate |
|||
| D064-25G | TOKU-E | 25 g | EUR 176.4 |
Doxycycline hydrate |
|||
| D064-5G | TOKU-E | 5 g | EUR 70.8 |
Cephalexin Hydrate |
|||
| C024-10G | TOKU-E | 10 g | EUR 249.6 |
Cephalexin Hydrate |
|||
| C024-25G | TOKU-E | 25 g | EUR 450 |
Cephalexin Hydrate |
|||
| C024-5G | TOKU-E | 5 g | EUR 158.4 |
Tivozanib (hydrate) |
|||
| C3415-10 | ApexBio | 10 mg | EUR 259.2 |
|
Description: Tivozanib, also known as AV-951 and KRN-951, is an orally active, ATP-competitive, small-molecule, quinoline-urea derivative. Tivozanib is a pan-VEGFR tyrosine kinase inhibitor. |
|||
Tivozanib (hydrate) |
|||
| C3415-5 | ApexBio | 5 mg | EUR 208.8 |
|
Description: Tivozanib, also known as AV-951 and KRN-951, is an orally active, ATP-competitive, small-molecule, quinoline-urea derivative. Tivozanib is a pan-VEGFR tyrosine kinase inhibitor. |
|||
FR122047 (hydrate) |
|||
| C5551-10 | ApexBio | 10 mg | EUR 247.2 |
|
Description: FR122047 is a selective inhibitor of cyclooxygenase (COX)-1 [1].Cyclooxygenase (COX)-1 is constitutively expressed in almost all tissues. COX-1 gene has been considered to be a ?housekeeping? gene. |
|||
FR122047 (hydrate) |
|||
| C5551-5 | ApexBio | 5 mg | EUR 164.4 |
|
Description: FR122047 is a selective inhibitor of cyclooxygenase (COX)-1 [1].Cyclooxygenase (COX)-1 is constitutively expressed in almost all tissues. COX-1 gene has been considered to be a ?housekeeping? gene. |
|||
FR122047 (hydrate) |
|||
| C5551-50 | ApexBio | 50 mg | EUR 877.2 |
|
Description: FR122047 is a selective inhibitor of cyclooxygenase (COX)-1 [1].Cyclooxygenase (COX)-1 is constitutively expressed in almost all tissues. COX-1 gene has been considered to be a ?housekeeping? gene. |
|||
Doripenem Hydrate |
|||
| E1KS1374 | EnoGene | 10mg | EUR 625.2 |
Cefadroxil (hydrate) |
|||
| C3991-1000 | ApexBio | 1 g | EUR 513.6 |
|
Description: Cefadroxil is a new semisynthetic cephalosporin with a broad antibacterial spectrum and a high chemotherapeutic potential [1]. In vitro: The inhibitory activity of this compound was similar to that of cephalexin and cephradine when tested against 602 clinical isolates on Mueller-Hinton medium. |
|||
Cefadroxil (hydrate) |
|||
| C3991-250 | ApexBio | 250 mg | EUR 195.6 |
|
Description: Cefadroxil is a new semisynthetic cephalosporin with a broad antibacterial spectrum and a high chemotherapeutic potential [1]. In vitro: The inhibitory activity of this compound was similar to that of cephalexin and cephradine when tested against 602 clinical isolates on Mueller-Hinton medium. |
|||
Cefadroxil (hydrate) |
|||
| C3991-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 135.6 |
|
Description: Cefadroxil is a new semisynthetic cephalosporin with a broad antibacterial spectrum and a high chemotherapeutic potential [1]. In vitro: The inhibitory activity of this compound was similar to that of cephalexin and cephradine when tested against 602 clinical isolates on Mueller-Hinton medium. |
|||
Cefadroxil (hydrate) |
|||
| C3991-500 | ApexBio | 500 mg | EUR 315.6 |
|
Description: Cefadroxil is a new semisynthetic cephalosporin with a broad antibacterial spectrum and a high chemotherapeutic potential [1]. In vitro: The inhibitory activity of this compound was similar to that of cephalexin and cephradine when tested against 602 clinical isolates on Mueller-Hinton medium. |
|||
Ivacaftor hydrate |
|||
| A3511-10 | ApexBio | 10 mg | EUR 320.4 |
|
Description: Description:IC50 Value: 25 nM (F508del-CFTR);100 nM (G551D-CFTR) [1]Ivacaftor (VX-770) is a CFTR Potentiator approved for patients with the G551D mutation of cystic fibrosis, which accounts for 4-5% cases of cystic fibrosis. |
|||
Ivacaftor hydrate |
|||
| A3511-100 | ApexBio | 100 mg | EUR 1470 |
|
Description: Description:IC50 Value: 25 nM (F508del-CFTR);100 nM (G551D-CFTR) [1]Ivacaftor (VX-770) is a CFTR Potentiator approved for patients with the G551D mutation of cystic fibrosis, which accounts for 4-5% cases of cystic fibrosis. |
|||
Ivacaftor hydrate |
|||
| A3511-5 | ApexBio | 5 mg | EUR 211.2 |
|
Description: Description:IC50 Value: 25 nM (F508del-CFTR);100 nM (G551D-CFTR) [1]Ivacaftor (VX-770) is a CFTR Potentiator approved for patients with the G551D mutation of cystic fibrosis, which accounts for 4-5% cases of cystic fibrosis. |
|||
Ivacaftor hydrate |
|||
| A3511-50 | ApexBio | 50 mg | EUR 1036.8 |
|
Description: Description:IC50 Value: 25 nM (F508del-CFTR);100 nM (G551D-CFTR) [1]Ivacaftor (VX-770) is a CFTR Potentiator approved for patients with the G551D mutation of cystic fibrosis, which accounts for 4-5% cases of cystic fibrosis. |
|||
CHAPS Hydrate |
|||
| 20-abx082319 | Abbexa |
|
|
Entecavir Hydrate |
|||
| A1767-25 | ApexBio | 25 mg | EUR 448.8 |
|
Description: Entecavir hydrate is a reverse transcriptase inhibitor.Reverse transcriptase (RT) is used to generate complementary DNA (cDNA) from an RNA template, which is mainly associated with retroviruses, such as HBV. |
|||
Entecavir Hydrate |
|||
| A1767-5 | ApexBio | 5 mg | EUR 170.4 |
|
Description: Entecavir hydrate is a reverse transcriptase inhibitor.Reverse transcriptase (RT) is used to generate complementary DNA (cDNA) from an RNA template, which is mainly associated with retroviruses, such as HBV. |
|||
Entecavir Hydrate |
|||
| A1767-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 135.6 |
|
Description: Entecavir hydrate is a reverse transcriptase inhibitor.Reverse transcriptase (RT) is used to generate complementary DNA (cDNA) from an RNA template, which is mainly associated with retroviruses, such as HBV. |
|||
Doripenem Hydrate |
|||
| A2036-10 | ApexBio | 10 mg | EUR 122.4 |
|
Description: Doripenem hydrate is a parenteral, potent, and well-balanced antibiotic against a wide range of both Gram+ and Gram- bacteria including Pseudomonas aeruginosa [1]. |
|||
Doripenem Hydrate |
|||
| A2036-100 | ApexBio | 100 mg | EUR 393.6 |
|
Description: Doripenem hydrate is a parenteral, potent, and well-balanced antibiotic against a wide range of both Gram+ and Gram- bacteria including Pseudomonas aeruginosa [1]. |
|||
Doripenem Hydrate |
|||
| A2036-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 135.6 |
|
Description: Doripenem hydrate is a parenteral, potent, and well-balanced antibiotic against a wide range of both Gram+ and Gram- bacteria including Pseudomonas aeruginosa [1]. |
|||
Doripenem Hydrate |
|||
| A2036-50 | ApexBio | 50 mg | EUR 268.8 |
|
Description: Doripenem hydrate is a parenteral, potent, and well-balanced antibiotic against a wide range of both Gram+ and Gram- bacteria including Pseudomonas aeruginosa [1]. |
|||
Calcipotriol hydrate |
|||
| 20-abx185970 | Abbexa |
|
|
Guanosine Hydrate |
|||
| B3678-200 | ApexBio | 200 mg | EUR 170.4 |
Felbamate hydrate |
|||
| B1145-10 | ApexBio | 10 mg | EUR 166.8 |
|
Description: Felbamate hydrate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) . |
|||
Felbamate hydrate |
|||
| B1145-50 | ApexBio | 50 mg | EUR 428.4 |
|
Description: Felbamate hydrate (FBM) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) . |
|||
Posaconazole hydrate |
|||
| B1225-10 | ApexBio | 10 mg | EUR 258 |
|
Description: Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme |
|||
Fluconazole hydrate |
|||
| B1226-1000 | ApexBio | 1 g | EUR 129.6 |
|
Description: Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. |
|||
Fluconazole hydrate |
|||
| B1226-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 129.6 |
|
Description: Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. |
|||
Fluconazole hydrate |
|||
| B1226-5000 | ApexBio | 5 g | EUR 268.8 |
|
Description: Fluconazole (hydrate) is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. |
|||
Tenofovir hydrate |
|||
| B1252-5 | ApexBio | 5 mg | EUR 150 |
|
Description: Tenofovir hydrate is an inhibitor of reverse transcriptase used for the treatment of the human immunodeficiency virus 1(HIV-1) and hepatitis B [1].Tenofovir hydrate is an antiviral pro-drug and the class of nucleoside reverse transcriptase inhibitor. |
|||
Tenofovir hydrate |
|||
| B1252-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 158.4 |
|
Description: Tenofovir hydrate is an inhibitor of reverse transcriptase used for the treatment of the human immunodeficiency virus 1(HIV-1) and hepatitis B [1].Tenofovir hydrate is an antiviral pro-drug and the class of nucleoside reverse transcriptase inhibitor. |
|||
Bosentan Hydrate |
|||
| B1521-100 | ApexBio | 100 mg | EUR 254.4 |
|
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor. |
|||
Bosentan Hydrate |
|||
| B1521-200 | ApexBio | 200 mg | EUR 366 |
|
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor. |
|||
Bosentan Hydrate |
|||
| B1521-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 150 |
|
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor. |
|||
Bosentan Hydrate |
|||
| B1521-50 | ApexBio | 50 mg | EUR 170.4 |
|
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor. |
|||
Bosentan Hydrate |
|||
| B1521-500 | ApexBio | 500 mg | EUR 686.4 |
|
Description: IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 ?M in P388/dx cells.A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor. |
|||
Amikacin hydrate |
|||
| B1657-50 | ApexBio | 50 mg | EUR 223.2 |
|
Description: Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. |
|||
Cefprozil hydrate |
|||
| B2142-10 | ApexBio | 10 mg | EUR 370.8 |
|
Description: Cefprozil hydrate |
|||
Cefprozil hydrate |
|||
| B2142-50 | ApexBio | 50 mg | EUR 1004.4 |
|
Description: Cefprozil hydrate |
|||
Sitafloxacin Hydrate |
|||
| B2150-10 | ApexBio | 10 mg | EUR 370.8 |
|
Description: Sitafloxacin Hydrate |
|||
Sitafloxacin Hydrate |
|||
| B2150-5 | ApexBio | 5 mg | EUR 224.4 |
|
Description: Sitafloxacin Hydrate |
|||
Sitafloxacin Hydrate |
|||
| B2150-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 296.4 |
|
Description: Sitafloxacin Hydrate |
|||
Sitafloxacin Hydrate |
|||
| B2150-S | ApexBio | Evaluation Sample | EUR 97.2 |
|
Description: Sitafloxacin Hydrate |
|||
(+)-Catechin hydrate |
|||
| N1692-20 | ApexBio | 20 mg | EUR 129.6 |
|
Description: An antioxidant flavonoid of plant origin; a free radical scavenger,preventing free radical-mediated damage in a variety of biological systems. For example,at physiological pH catechin suppressed DNA strand breaks by hydroxyl radicals. It has also been s |
|||
(+)-Catechin hydrate |
|||
| N1692-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 129.6 |
|
Description: An antioxidant flavonoid of plant origin; a free radical scavenger,preventing free radical-mediated damage in a variety of biological systems. For example,at physiological pH catechin suppressed DNA strand breaks by hydroxyl radicals. It has also been s |
|||